Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-915
- Development stage
- Preclinical
- Lead developer
- Avidin
- Modality
- Small Molecules
01
Overview
AC-915 is a novel amino-trifluoro-phthalimide analog being investigated for the treatment of hepatocellular carcinoma (HCC). It functions by binding to lipid droplets and the endoplasmic reticulum (ER) membrane, where it interacts with several chaperone proteins, including HSP60, HSP70, HSP90, and protein disulfide isomerase (PDI). AC-915 specifically inhibits PDI activity, leading to the induction of cell death in HCC cells and the inhibition of cell proliferation and migration. In vivo studies in mouse models have demonstrated that the compound preferentially accumulates in the liver and significantly reduces tumor incidence and size. The compound possesses inherent blue fluorescence, which facilitates biodistribution analysis in native tissue sections.
- Other names
- amino-trifluoro-phthalimide analog
Beyond the preview
Go deeper on AC-915.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AC-915.